Vanguard Global Advisers
TVTX icon

Vanguard Global Advisers’s Travere Therapeutics TVTX Stock Holding History

Vanguard Global Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
40,535
+2,437
+6% +$108K ﹤0.01% 1164
2026
Q1 		$1.13M Buy
+38,098
New +$1.14M ﹤0.01% 1580

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's TVTX Position: Q2 2026 in Review

Vanguard Global Advisers increased its Travere Therapeutics (TVTX) stake by 6.4% in Q2 2026, buying an estimated $108K and bringing the position to 40,535 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1164.

Vanguard Global Advisers first reported a position in TVTX in Q1 2026 and has held it in 2 quarters since. 316 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Vanguard Global Advisers held 40,535 shares of Travere Therapeutics worth $2.3M as of Q2 2026.
  • Vanguard Global Advisers bought 2,437 Travere Therapeutics shares in Q2 2026, an estimated $108K.
  • Travere Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1164 holding.
  • Vanguard Global Advisers first reported a position in Travere Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 316 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.